Neonatal and Pediatric Oral HSV‑1: Risks, Prevention, and Management

Transmission and Clinical Presentation

Post‑natal HSV‑1 transmission to newborns can cause severe disease with high mortality and morbidity; untreated disseminated disease carries ≈ 80 % mortality. [CDC MMWR 2004] [1][2]
Neonatal HSV infection presents in three distinct patterns (CDC MMWR 2004):
- Disseminated multiorgan disease – ≈ 25 % of cases; ≈ 80 % mortality without therapy. [1][2]
- Central nervous system (CNS) disease – ≈ 35 % of cases; frequently leads to severe neurologic sequelae. [1][2]
- Localized skin‑eye‑mouth disease – ≈ 40 % of cases. [1][2]
Clinical onset typically occurs 9–11 days after birth, though timing varies by disease form. [1][2]
Vesicular rash is absent in ~40 % of infants with CNS or disseminated disease, making early diagnosis difficult. [1][2]
In infants 1–6 months old, primary HSV‑1 infection commonly presents with fever, irritability, tender submandibular lymphadenopathy, and painful superficial oral ulcers. [1][2]
After 6 months of age, primary gingivostomatitis becomes more frequent but is generally milder; orolabial disease is the most common manifestation in this age group. [1][2]
Immunocompromised children are at risk for severe local lesions or disseminated HSV disease. [1][2]

Persons with active oral herpes lesions must avoid any direct contact (including kissing) with newborns and young infants. [CDC MMWR 1999] [3][4]
Contact should be avoided whenever herpetic (orolabial) lesions are visible. [3][4]
Asymptomatic viral shedding can occur, but the transmission risk is highest when visible lesions are present. [CDC MMWR 2004] [1][5]

Acyclovir is the drug of choice for all neonatal HSV infections (CDC MMWR 2004; expert consensus). [1][6]
Neonates (birth‑to 1 month)
- Disseminated or CNS disease – Acyclovir 20 mg/kg IV every 8 h for 21 days (strong recommendation). 6
- Skin‑eye‑mouth disease – Acyclovir 20 mg/kg IV every 8 h for 14 days (strong recommendation). 6
- Diagnostic monitoring – Repeat CSF HSV DNA PCR between days 19‑21 and continue therapy until PCR is negative. 6
Children > 1 month (weight‑based dosing)
- Disseminated or CNS disease – Acyclovir 10 mg/kg IV every 8 h for 21 days (expert opinion). 6
- Moderate‑to‑severe gingivostomatitis – Acyclovir 5‑10 mg/kg IV every 8 h until oral lesions regress, then switch to oral therapy (expert opinion). 6
- Mild gingivostomatitis or mucocutaneous HSV – Acyclovir 20 mg/kg orally (max 400 mg) three times daily for 5‑10 days (expert opinion). 6

Adequate hydration and renal‑function monitoring are essential during IV acyclovir therapy (expert consensus). 6
Reversible nephropathy occurs in up to 20 % of patients, typically after ≈ 4 days of treatment (moderate‑level evidence). 6
Neutropenia has been reported in up to 46 % of neonates receiving long‑term suppressive acyclovir, but it is usually self‑limited (moderate‑level evidence). 6

Absence of skin lesions does not exclude HSV infection; only ≈ 60 % of infants with disseminated or CNS disease display vesicles (CDC MMWR 2004). [1][2]
Maintain a high index of suspicion for HSV in any newborn with a septic appearance or CNS symptoms, regardless of lesion presence (CDC MMWR 2004). [1][2]